IASO Bio’s CAR-T Therapy Fucaso Accepted for Review in Singapore
China-based IASO Biotherapeutics has announced that a New Drug Application (NDA) for its BCMA-targeted chimeric...
Novartis Reports 12% YOY Growth in Full-Year Net Sales
Swiss pharmaceutical major Novartis (NYSE: NVS) has released its Q4 and full-year 2024 financial report,...
Takeda Reports 4.5% Revenue Growth in First Nine Months of Fiscal Year
Japan-headquartered Takeda (NYSE: TAK, TYO: 4502) has released its financial results for the 9-month period...
Daiichi Sankyo Reports 16.6% Revenue Growth in First Three Quarters of FY2024
Japan-based Daiichi Sankyo (TYO: 4568) has reported revenues of JPY 1.37 trillion ($8.927 billion) for...
Pfizer Reports 7% Revenue Growth in 2024, Expects Steady Performance in 2025
US major Pfizer Inc. (NYSE: PFE) has released its financial results for the fourth quarter...
China’s MoC Lists US Firms PVH and Illumina as Unreliable Entities
China’s Ministry of Commerce (MoC) has released a list of unreliable entities, including US firms...
Roche Reports 7% Growth in Full-Year Sales, Strength in Pharmaceuticals
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q4 and full-year 2024 financials, reporting a...
Sanofi Reports Strong Q4 Growth, Plans EUR 5 Billion Share Buyback
French pharmaceutical giant Sanofi (NASDAQ: SNY) reported a strong fourth-quarter performance with 10.3% year-on-year (YOY)...
Xtalpi Partners with JW Pharmaceutical to Enhance Drug Discovery with AI
Shenzhen-based QuantumPharm Inc. (HKG: 2228), better known as Xtalpi Inc., a global leader in AI-powered...
DeepSeek’s AI: Transforming Drug Development and Healthcare in China
DeepSeek, a Chinese artificial intelligence company, is poised to make a significant impact on the...
MediLink Therapeutics’ YL217 Receives FDA IND Clearance for Novel ADC Targeting Gastrointestinal Cancers
MediLink Therapeutics, a clinical-stage biotech company, announced today that its internally developed antibody-drug conjugate (ADC),...
AbbVie’s 2024 Revenue Grows Despite Humira Decline, Skyrizi and Rinvoq Surge
US-based pharmaceutical giant AbbVie (NYSE: ABBV) reported its 2024 financial results on January 31, with...
PegBio’s Lead Product PB-119 Clears HKEX Hearing for Type 2 Diabetes and Obesity Treatment
On January 28, 2025, the Hong Kong Stock Exchange (HKEX) website showed that PegBio Co.,...
Roche Reports 7% Revenue Growth in 2024, Driven by Oncology and Ophthalmology
Roche (SWX: ROG) released its 2024 annual financial report on January 30, showing a 7%...
DeepSeek Enhances Biopharma IND and NDA Processes with AI
In the regulatory submissions for Investigational New Drug (IND) and New Drug Application (NDA) in...
Enhertu Approved by FDA for HR-Positive, HER2-Low Breast Cancer
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) jointly announced that their co-developed antibody-drug...
Vigonvita Life Sciences Targets HKEX IPO with Integrated Biopharma Model
On January 27, 2025, the Hong Kong Stock Exchange (HKEX) website displayed that Suzhou Vigonvita...
CStone Pharmaceuticals Partners with SteinCares for Sugemalimab Commercialization in Latin America
CStone Pharmaceuticals (HKG: 2616), a China – based biopharmaceutical company focused on oncology drug development,...
MicroPort’s Fireliums Receives NMPA Approval for Coronary Bifurcation Stenosis Treatment
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...
MicroPort’s TomaHawk Intravascular Shock Wave Therapy Device Approved by NMPA
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) has announced receiving marketing approval from...